LON:VEC - Vectura Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 81.25 +0.45 (+0.56 %)
(As of 06/20/2018 10:49 AM ET)
Previous CloseGBX 80.80
Today's RangeGBX 80.10 - GBX 82
52-Week RangeGBX 70 - GBX 166.97
Volume441,819 shs
Average Volume4.61 million shs
Market Capitalization£528.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vectura Group logoVectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company's marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions. Its generic products include VR315, VR506, and VR632 for the treatment of asthma; and Phase III clinical stage products include VR475 for the treatment of severe adult asthma, and VR876 for the treatment of lung diseases, as well as NVA237 and QVA149 for the treatment of COPD for which filed NDA to the Food and Drug Administration. Its Phase II clinical stage products comprise VR096 for anti-inflammatory asthma and COPD; VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; and VR736 for the treatment severe influenza. The company's Phase I clinical stage products include VR942 for the treatment of asthma; VR475 for the treatment of severe adult asthma; and VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage product includes VR588 for the treatment of inflammatory airway diseases. The company also provides patent-protected technology platforms, such as PowderHale, a formulation technology that is designed to enhance the performance of inhaled formulations; PowderMax, a technology that applies PowderHale approach to create high performance dry powder formulations; and ParticleMax, spray drying particle engineering technology to deliver dry powder biologics. In addition, it provides dry powder inhalers; nebulizer delivery systems; and AKITA Jet, APIXNEB, and FOX devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Receive VEC News and Ratings via Email

Sign-up to receive the latest news and ratings for VEC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:VEC
CUSIPN/A
Phone+44-1249-667700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-48.35%
Return on Equity-11.44%
Return on Assets-9.24%

Miscellaneous

EmployeesN/A
Outstanding Shares679,350,000

Vectura Group (LON:VEC) Frequently Asked Questions

What is Vectura Group's stock symbol?

Vectura Group trades on the London Stock Exchange (LON) under the ticker symbol "VEC."

What price target have analysts set for VEC?

9 equities research analysts have issued 12 month price objectives for Vectura Group's shares. Their forecasts range from GBX 105 to GBX 160. On average, they anticipate Vectura Group's share price to reach GBX 134.56 in the next twelve months. View Analyst Ratings for Vectura Group.

Who are some of Vectura Group's key competitors?

Who are Vectura Group's key executives?

Vectura Group's management team includes the folowing people:
  • Mr. James Ward-Lilley BA, MBA, CEO & Exec. Director (Age 53)
  • Mr. Andrew Derodra, CFO & Exec. Director (Age 52)
  • Elizabeth Knowles, Director of Investor Relations & Analysis
  • Mr. John Murphy, Gen. Counsel & Company Sec. (Age 65)
  • Fleur Wood, Director of Communications

Has Vectura Group been receiving favorable news coverage?

Headlines about VEC stock have been trending positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vectura Group earned a coverage optimism score of 0.33 on Accern's scale. They also gave media coverage about the company an impact score of 46.64 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Vectura Group?

Shares of VEC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Vectura Group's stock price today?

One share of VEC stock can currently be purchased for approximately GBX 81.25.

How big of a company is Vectura Group?

Vectura Group has a market capitalization of £528.41 million.

How can I contact Vectura Group?

Vectura Group's mailing address is One Prospect West, CHIPPENHAM, SN14 6FH, United Kingdom. The company can be reached via phone at +44-1249-667700.


MarketBeat Community Rating for Vectura Group (VEC)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  739 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  940
MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote "Outperform" if you believe VEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.